Procainamide Dosing for Ventricular Tachycardia Conversion

Introduction to Procainamide Administration

• The American Heart Association recommends procainamide administration at 20-50 mg/min until arrhythmia suppression occurs, with a typical effective dose range of 500-1000 mg (approximately 7.5-15 mg/kg) for conversion of hemodynamically stable monomorphic VT 1

Critical Monitoring Parameters

• The American College of Cardiology suggests stopping the infusion immediately if arrhythmia suppression occurs, hypotension develops, QRS duration prolongs by ≥50% from baseline, or a total cumulative dose of 17 mg/kg is reached 1
• The maximum cumulative dose of procainamide should not exceed 17 mg/kg to minimize the risk of adverse effects 2

Important Clinical Considerations

• The American College of Cardiology positions procainamide as a second-line therapy for VT, after lidocaine and bretylium, according to the 1996 ACC/AHA guidelines 3
• The American Heart Association gives procainamide no specific recommendation for cardiac arrest, noting it was studied as a second-tier agent with no survival benefit demonstrated in the 2015 AHA guidelines 4

Special Populations and Contraindications

• Procainamide should be avoided or used with extreme caution in patients with QT prolongation, congestive heart failure, renal insufficiency, or hypotension at baseline, due to increased risk of adverse effects 1, 2, 3